Brooklyn ImmunoTherapeutics Announces Name Change To Eterna Therapeutics And Provides Corporate Updates

10/11/22 8:35:36 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BTX alert in real time by email

New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio

The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines

Company's shares to trade under new ticker symbol "ERNA" starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date

Get the next $BTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BTX

Date	Price Target	Rating	Analyst
12/29/2021	$9.00	Overweight	Cantor Fitzgerald
10/6/2021	$20.00	Buy	Maxim Group

More analyst ratings

$BTX
Press Releases

Fastest customizable press release news feed in the world

Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company's shares to trade under new ticker symbol "ERNA" starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), today announces that it is changing its name to Eterna Therapeutics Inc. ("Eterna") to reflect its focus on developing advanced therapies using its extens
10/11/22 8:30:00 AM ET
$BTX
Biotechnology: Pharmaceutical Preparations
Health Care
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company") today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The primary endpoint of the study was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. One hundred and fifty patients were enrolled in the study. At two years of follow-up in the intention-to-treat (ITT, n=105) population the median EFS was 48.3 months and was not reached in the control arm (Hazard
7/26/22 7:30:00 AM ET
$BTX
Biotechnology: Pharmaceutical Preparations
Health Care
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, it received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq"), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company's common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no imm
6/17/22 5:00:00 PM ET
$BTX
Biotechnology: Pharmaceutical Preparations
Health Care

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief
5/31/22 7:30:00 AM ET
$BTX
Biotechnology: Pharmaceutical Preparations
Health Care
Amarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta
5/19/22 8:23:13 AM ET
$AMRN
$BTX
Biotechnology: Pharmaceutical Preparations
Health Care
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati
1/20/22 7:30:00 AM ET
$BTX
Biotechnology: Pharmaceutical Preparations
Health Care

Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the fourth quarter and year ended December 31, 2021. Financial and corporate highlights for the quarter and year months ended December 31, 2021 and subsequently include the following: Fourth quarter ended December 31, 2021: Appointed Susan McClatchey as Vice President and Head of QualityNamed to both the Nasdaq Biotechnology Index and the ICE Biotechnology Ind
4/15/22 4:15:00 PM ET
$BTX
Biotechnology: Pharmaceutical Preparations
Health Care
Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the quarter ended September 30, 2021. Financial and corporate highlights for the quarter ended September 30, 2021 and subsequently include the following: Transitioned from the NYSE American to the Nasdaq Global Market to better align with industry peersCompleted the acquisition of Novellus TherapeuticsAppointed Roger Sidhu, M.D. as chief medical officer, Jay Sial
11/9/21 4:35:00 PM ET
$BTX
Biotechnology: Pharmaceutical Preparations
Health Care
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted on September 20, 2021 by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D., with guest contributor Matt Angel, Ph.D., Factor Bioscience's Co-founder and Chief Executive Officer. The call was based on Brooklyn's most recent corporate slide deck, which can be found here. Highlights of the call included: Brooklyn
9/21/21 8:30:00 AM ET
$BTX
Biotechnology: Pharmaceutical Preparations
Health Care

Brooklyn ImmunoTherapeutics Announces Name Change To Eterna Therapeutics And Provides Corporate Updates

Chat with this insight

Recent Analyst Ratings for $BTX

$BTX SEC Filings

Brooklyn ImmunoTherapeutics Inc. filed SEC Form 8-K: Leadership Update

SEC Form 424B3 filed by Brooklyn ImmunoTherapeutics Inc.

SEC Form EFFECT filed by Brooklyn ImmunoTherapeutics Inc.

$BTX Market Insights

Live Market Insights

Maxim Group Downgrades Brooklyn to Hold

Brooklyn ImmunoTherapeutics Announces 1-For-20 Share Consolidation